75th SCIENTIFIC SESSIONS CORPORATE SYMPOSIA AT-A-GLANCE FRIDAY, JUNE 5, 2015: 8:00 a.m. – 1:45 p.m. Turning Words into Action in Type 2 Diabetes Sponsored by Institute for Medical and Nursing Education, Inc. And International Medical Press Supported by an educational grant from AstraZeneca Contact: Edwin Odoemelam Phone: +44-207-398-0608 Email: [email protected] Location: Westin Boston Waterfront, Harbor Ballroom This highly interactive workshop is organized by the Global Partnership for Effective Diabetes Management and is designed for healthcare professionals from around the globe, focusing on the need for early glycemic control to reduce diabetes-related complications, and discussion on how to overcome barriers to achieving goals safely. 6:30 p.m. – 9:30 p.m. 6:30 p.m. – 7:00 p.m. – Registration and Dinner 7:00 p.m. – 9:30 p.m. – Educational Program El Panorama Cambiante Sobre el Tratamiento de la Diabetes Tipo 2 con Insulina (Presentado en Español) Jointly sponsored by University of Texas Southwestern Medical Center and Worldwide Initiative for Diabetes Education Supported by an unrestricted educational grant from Novo Nordisk Contacts: Mark Vinciguerra, University of Texas Southwestern Medical Center Phone/Email: 214-648-4852; [email protected] Jane Savio, Worldwide Initiative for Diabetes Education Phone/Email: 212-614-4337; [email protected] Location: Westin Boston Waterfront, Harbor Ballroom Este simposio se enfocará en insulinas y nuevas tendencias en terapias de insulina, como es que están redefiniendo el cuidado de la diabetes tipo 2 hoy en día y que esperanza están aportando para hacer frente a la creciente demanda mundial debido al crecimiento de la diabetes y sus complicaciones. 6:30 p.m. – 9:30 p.m. 6:30 p.m. – 7:00 p.m. – Program Registration and Buffet Dinner 7:00 p.m. – 9:00 p.m. – CME Scientific Program Novel Mechanisms and Advancing Therapeutic Paradigms for Optimizing LDL-Focused Management and Cardioprotection in the Diabetic Patient Sponsored by CMEducation Resources Updated 5/14/15 (for website) Supported by an educational grant from Sanofi US-Regeneron Contact: Milo Falcon Phone: 888-977-1625 Location: Boston Marriott Copley Place, Grand Ballroom G-K This symposium will discuss novel mechanisms and advancing therapeutic paradigms for optimizing LDL- focused management and cardioprotection in diabetic patients. It will focus on clinical trials, mechanisms of atherosclerotic heart disease, novel LDL targets and therapies, and new translational dimensions of applying advances in LDL reduction to the diabetes population. 6:30 p.m. - 9:30 p.m. 6:30 p.m. – 7:00 p.m. - Dinner 7:00 p.m. – 9:30 p.m. – Program Comprehensive Management of DM - Focus on SGLT2 Inhibitors and Combination Therapy - Emerging Concepts of Renal Effects Provided by Metabolic Endocrine Education Foundation, PESI Inc., and Medtelligence Supported by an educational grant from AstraZeneca Contact: Chris Archibald Phone: 732-977-5887 Email: [email protected] Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom The overall objective of this CME program is to describe the management of diabetes, discussing early combination therapy and how to achieve goals safely without hypoglycemia or weight gain. The varied effects of newer agents, including SGLT2 inhibitors and incretin-based therapy (DPP4 inhibitors and GLP1 receptor agonists), and their potential combinations will be evaluated. The efficacy of such approaches in glycemic control, the effects on weight and blood pressure, and emerging information about potential positive effects on renal function will be addressed, providing expert insight on the implications of these findings for the long-term management of diabetes. Faculty: Zachary T. Bloomgarden, MD, Chair, Yehuda Handelsman, MD, Chair, Stefano Del Prato, MD, Lawrence A. Leiter, MD, Matthew R. Weir, MD You may view the Agenda and program information at: http://metabolicfoundation.com/ada2015 SATURDAY, JUNE 6, 2015: 5:30 a.m.- 7:30 a.m. 5:30 a.m. – 6:00 a.m. – Breakfast 6:00 a.m. – 7:30 a.m. – Symposium Clinical Issues in Type 2 Diabetes: Discussions and Debates Around GLP-1 Receptor Agonists Jointly provided by Clinical and Patient Educators Association and Integritas Communications Supported by an educational grant from AstraZeneca Contact: Barbara Jean Wynne Phone: 201-535-4941 Updated 5/14/15 (for website) Location: Boston Marriott Copley Place, Grand Ballroom G-K During this Clinical Issues™ program, experts in diabetes research and patient care will discuss and debate a set of topics related to the potential clinical roles of GLP-1 receptor agonists. Throughout the program, the faculty panel will provide practical consensus recommendations for areas in which published evidence for GLP-1 receptor agonists has only recently emerged. 5:30 a.m.- 7:45 a.m. Insulin-Based Options: Current Treatment Strategies and the Potential Impact of Emerging Options on Patient Outcomes 5:30 a.m. – 5:45 a.m. – Breakfast & Arrivals 5:45 a.m. – 7:45 a.m. – Symposium Sponsored by Global Directions in Medicine, Inc. Supported by an educational grant from Novo Nordisk, Inc. Contact: Deanna Schuly Email: [email protected] Location: Boston Marriott Copley Place, Grand Ballroom A-F This symposium is designed to improve clinicians’ awareness of the significance of timely glycemic management and initiating and intensifying insulin treatment when appropriate. The latest evidence- based information on emerging insulin therapy, which may help to achieve glycemic goals with lower risks of hypoglycemia and weight gain, will be reviewed. 5:30 a.m.- 7:45 a.m. Managing the High Risk Patient – LDL and Beyond: Contemporary and Future Approaches Provided by Metabolic Endocrine Education Foundation, PESI Inc., and Medtelligence Supported by educational grants from Amgen, Inc. and Amarin Pharma Inc. Contact: Chris Archibald Phone: 732-977-5887 Email: [email protected] Location: Westin Boston Waterfront, Harbor Ballroom Despite the availability of numerous clinical guidelines for the management of lipids to reduce cardiovascular disease (CVD), appropriate application of these guidelines remains low, likely contributing to CVD morbidity and mortality. The overall objectives of this CME program are to examine the prevalence of CVD in the high-risk patient, discuss and contrast guidelines, provide an update on pharmacological strategies to reduce CVD risk, and discuss expert insights into how to apply the lipid management guidelines and applicable treatment target goals to achieve better patient outcomes. Faculty: Yehuda Handelsman, MD, Chair, Lawrence A. Leiter, MD, Jorge Plutzky, MD, James A. Underberg, MD, MS, and Howard S. Weintraub, MD 6:15 p.m. - 8:45 p.m. 6:15 p.m. – 7:00 p.m. – Registration and Dinner 7:00 p.m. – 8:45 p.m. – Symposium Updated 5/14/15 (for website) Seeing into the Future: Preventing, Diagnosing and Treating Diabetic Eye Disease Sponsored by FocusCME Supported by educational grants from Regeneron Pharmaceuticals and Allergan, Inc. Contact: Steven Scrivner Email: [email protected] Location: Boston Marriott Copley Place, Grand Ballroom G-K The goal of this activity is to reinforce traditional strategies and educate clinicians about new strategies for managing the eye health of patients with diabetes. An emphasis will be placed on the need for enhanced communication with the eye care specialist, as well as a general understanding of the therapeutic options available to aid in patient counseling. Faculty: John E. Anderson, MD; Ralph A. DeFronzo, MD; John W. Kitchens, MD 6:15 p.m. - 9:00 p.m. 6:15 p.m. – 7:00 p.m. – Registration and Dinner 7:00 p.m. – 9:00 p.m. – Scientific Program Patient-Centered Management of Type 2 Diabetes: A Focus on the Newer Antihyperglycemic Agents Sponsored by Institute for Medical and Nursing Education, Inc. Supported by an educational grant from AstraZeneca Contact: Katie Fidanza Phone: 404-443-1511 Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom Current type 2 diabetes mellitus (T2DM) treatment guidelines emphasize individualized glycemic targets and patient-centered treatment regimens. This highly interactive symposium will use standardized patients to demonstrate effective techniques for providing patient-centered T2DM care using newer classes of antihyperglycemic agents, including dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors. Practical, evidence-based recommendations for individualizing therapy in T2DM patients with common comorbidities— cardiovascular disease, chronic kidney disease, or obesity will be featured. 6:15 p.m. - 9:15 p.m. Eighth Annual Gerald J. Friedman Fellows Symposium "Nutrition, Diabetes and Human Health" Sponsored by Tufts University, Friedman School of Nutrition Science and Policy Supported by an educational grant from Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research Contact: Leonid Poretsky, MD Phone: 212-434-3662 Location: Westin Boston Waterfront, Harbor Ballroom Since 2000 the Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research has supported the work of 41 research fellows (for details see http://friedmanfellows.com/fellows/). The Updated 5/14/15 (for website) 8th Annual Friedman Fellows Symposium will have the following program: Oral and poster presentation; A debate titled, “Obesity, Nature and Nurture” with plenary speakers Drs. Jeffrey Flier and Terry Maratos-Flier